Advances in targeted therapies and new promising targets in esophageal cancer

Abbes Belkhiri, Wael El-Rifai

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Esophageal cancer, comprising squamous carcinoma and adenocarcinoma, is a leading cause of cancer-related death in the world. Notably, the incidence of esophageal adenocarcinoma has increased at an alarming rate in the Western world. Unfortunately, the standard first-line chemo-radiotherapeutic approaches are toxic and of limited efficacy in the treatment of a significant number of cancer patients. The molecular analysis of cancer cells has uncovered key genetic and epigenetic alterations underlying the development and progression of tumors. These discoveries have paved the way for the emergence of targeted therapy approaches. This review will highlight recent progress in the development of targeted therapies in esophageal cancer. This will include a review of drugs targeting receptor tyrosine kinases and other kinases in esophageal cancer. Additional studies will be required to develop a rational integration of these targeted agents with respect to histologic types of esophageal cancer and the optimal selection of cancer patients who would most likely benefit from targeted therapy. Identification of AURKA and AXL as key molecular players in esophageal tumorigenesis and drug resistance strongly justifies the evaluation of the available drugs against these targets in clinical trials.

Original languageEnglish (US)
Pages (from-to)1348-1358
Number of pages11
JournalOncotarget
Volume6
Issue number3
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Esophageal Neoplasms
Neoplasms
Adenocarcinoma
Aurora Kinase A
Drug Receptors
Therapeutics
Western World
Drug Evaluation
Poisons
Drug Delivery Systems
Drug Resistance
Epigenomics
Protein-Tyrosine Kinases
Patient Selection
Squamous Cell Carcinoma
Carcinogenesis
Phosphotransferases
Clinical Trials
Incidence

Keywords

  • Adenocarcinoma
  • Cancer
  • Esophageal
  • Gastric
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Advances in targeted therapies and new promising targets in esophageal cancer. / Belkhiri, Abbes; El-Rifai, Wael.

In: Oncotarget, Vol. 6, No. 3, 01.01.2015, p. 1348-1358.

Research output: Contribution to journalArticle

@article{3a6bdd8512e64079aa8f1c9c1ebafed2,
title = "Advances in targeted therapies and new promising targets in esophageal cancer",
abstract = "Esophageal cancer, comprising squamous carcinoma and adenocarcinoma, is a leading cause of cancer-related death in the world. Notably, the incidence of esophageal adenocarcinoma has increased at an alarming rate in the Western world. Unfortunately, the standard first-line chemo-radiotherapeutic approaches are toxic and of limited efficacy in the treatment of a significant number of cancer patients. The molecular analysis of cancer cells has uncovered key genetic and epigenetic alterations underlying the development and progression of tumors. These discoveries have paved the way for the emergence of targeted therapy approaches. This review will highlight recent progress in the development of targeted therapies in esophageal cancer. This will include a review of drugs targeting receptor tyrosine kinases and other kinases in esophageal cancer. Additional studies will be required to develop a rational integration of these targeted agents with respect to histologic types of esophageal cancer and the optimal selection of cancer patients who would most likely benefit from targeted therapy. Identification of AURKA and AXL as key molecular players in esophageal tumorigenesis and drug resistance strongly justifies the evaluation of the available drugs against these targets in clinical trials.",
keywords = "Adenocarcinoma, Cancer, Esophageal, Gastric, Targeted therapy",
author = "Abbes Belkhiri and Wael El-Rifai",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.2752",
language = "English (US)",
volume = "6",
pages = "1348--1358",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "3",

}

TY - JOUR

T1 - Advances in targeted therapies and new promising targets in esophageal cancer

AU - Belkhiri, Abbes

AU - El-Rifai, Wael

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Esophageal cancer, comprising squamous carcinoma and adenocarcinoma, is a leading cause of cancer-related death in the world. Notably, the incidence of esophageal adenocarcinoma has increased at an alarming rate in the Western world. Unfortunately, the standard first-line chemo-radiotherapeutic approaches are toxic and of limited efficacy in the treatment of a significant number of cancer patients. The molecular analysis of cancer cells has uncovered key genetic and epigenetic alterations underlying the development and progression of tumors. These discoveries have paved the way for the emergence of targeted therapy approaches. This review will highlight recent progress in the development of targeted therapies in esophageal cancer. This will include a review of drugs targeting receptor tyrosine kinases and other kinases in esophageal cancer. Additional studies will be required to develop a rational integration of these targeted agents with respect to histologic types of esophageal cancer and the optimal selection of cancer patients who would most likely benefit from targeted therapy. Identification of AURKA and AXL as key molecular players in esophageal tumorigenesis and drug resistance strongly justifies the evaluation of the available drugs against these targets in clinical trials.

AB - Esophageal cancer, comprising squamous carcinoma and adenocarcinoma, is a leading cause of cancer-related death in the world. Notably, the incidence of esophageal adenocarcinoma has increased at an alarming rate in the Western world. Unfortunately, the standard first-line chemo-radiotherapeutic approaches are toxic and of limited efficacy in the treatment of a significant number of cancer patients. The molecular analysis of cancer cells has uncovered key genetic and epigenetic alterations underlying the development and progression of tumors. These discoveries have paved the way for the emergence of targeted therapy approaches. This review will highlight recent progress in the development of targeted therapies in esophageal cancer. This will include a review of drugs targeting receptor tyrosine kinases and other kinases in esophageal cancer. Additional studies will be required to develop a rational integration of these targeted agents with respect to histologic types of esophageal cancer and the optimal selection of cancer patients who would most likely benefit from targeted therapy. Identification of AURKA and AXL as key molecular players in esophageal tumorigenesis and drug resistance strongly justifies the evaluation of the available drugs against these targets in clinical trials.

KW - Adenocarcinoma

KW - Cancer

KW - Esophageal

KW - Gastric

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84922716635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922716635&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.2752

DO - 10.18632/oncotarget.2752

M3 - Article

C2 - 25593196

AN - SCOPUS:84922716635

VL - 6

SP - 1348

EP - 1358

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 3

ER -